Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START a trial

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3472-3479

  Apperley, Jane F ^a   Cortes, Jorge E ^a   Kim, Dong Wook ^a   Roy, Lydia ^a   Roboz, Gail J ^a   Rosti, Gianantonio ^a   Bullorsky, Eduardo O ^a   Abruzzese, Elisabetta ^a   Hochhaus, Andreas ^a   Heim, Dominik ^a   De Souza, Carmino A ^a   Larson, Richard A ^a   Lipton, Jeffrey H ^a   Khoury, H Jean ^a   Kim, Hyeoung Joon ^a   Sillaber, Christian ^a   Hughes, Timothy P ^a   Erben, Philipp ^a   Van Tornout, Jan ^a   Stone, Richard M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BCR ABL PROTEIN; DASATINIB; HYDROXYUREA; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ACUTE LYMPHOBLASTIC LEUKEMIA; DISEASE FREE SURVIVAL; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; THIAZOLES; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70249141675     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.3339     Document Type: Article

References (30)

1. Ries LAG, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2004. National Cancer Institute, Bethesda, MD, 2006. http://seer.cancer. gov/csr/1975-2004
2. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006
3. Lahaye T, Riehm B, Berger U, et al: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 103:1659-1669, 2005
4. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002
5. Kantarjian H, Talpaz M, O'Brien S, et al: Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia: Comparison with historic experience. Cancer 103:2099-2108, 2005
6. Gratwohl A, Brand R, Apperley J, et al: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results - An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513-521, 2006
7. Grigg A, Hughes T: Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant 12:795-807, 2006
8. Radich JP, Dai H, Mao M, et al: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103:2794-2799, 2006
9. Dai Y, Rahmani M, Corey SJ, et al: A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279:34227-34239, 2004
10. Donato NJ, Wu JY, Stapley J, et al: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690-698, 2003
11. Lionberger JM, Wilson MB, Smithgall TE: Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 275:18581-18585, 2000
12. Roginskaya V, Zuo S, Caudell E, et al: Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 13:855-861, 1999
13. Hu Y, Swerdlow S, Duffy TM, et al: Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 103:16870-16875, 2006
14. Tokarski JS, Newitt JA, Chang CY, et al: The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790-5797, 2006
15. Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004
16. O'Hare T, Walters DK, Stoffregen EP, et al: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505, 2005
17. Hochhaus A, Kantarjian HM, Baccarani M, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309, 2007
18. Guilhot F, Apperley J, Kim DW, et al: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143-4150, 2007
19. Kantarjian H, Pasquini R, Hamerschlak N, et al: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase-II trial. Blood 109: 5143-5150, 2007
20. Cortes J, Rousselot P, Kim DW, et al: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213, 2007
21. Ottmann O, Dombret H, Baccarani M, et al: Dasatinib (BMS-354825) induces rapid hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia: Interim results of a phase II study. Blood 110:2309-2315, 2007
22. NCCN: Clinical Practice Guidelines in Oncology(TM): Chronic myelogenous leukemia, V.3.2008. http://www.nccn.org/professionals/physician-gls/PDF/cml.pdf
23. Kantarjian HM, Deisseroth A, Kurzrock R, et al: Chronic myelogenous leukemia: A concise update. Blood 82:691-703, 1993
24. Clopper C, Pearson E: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
25. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
26. Silver RT, Talpaz M, Sawyers CL, et al: Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 104:11a, 2004 (abstr 23)
27. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
28. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196, 2002
29. Quintás-Cardama A, Kantarjian HM, Nicaise C, et al: Cytopenias in patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with dasatinib (SPRYCEL): Clinical features and management, including outcome after hematopoietic growth factor therapy. Blood 108:613a, 2006 (abstr 2163)
30. Quintás-Cardama A, Kantarjian HM, O'Brien S, et al: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914, 2007